New imaging methods for detecting brain tumors in patients with metastasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of advanced imaging techniques, specifically positron emission tomography (PET) and magnetic resonance imaging (MRI), in detecting cancerous tissue in patients with brain metastasis. Participants will undergo a PET/MRI scan followed by a separate MRI scan with a tracer, with the entire process lasting about three hours. The study seeks to determine if these new imaging methods can identify tumors more accurately than existing imaging technologies, potentially leading to better cancer treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Able and willing to provide informed consent
* Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
* Received radiation therapy at some point in the last 2 years
* Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which would include immunotherapy, targeted therapy, or systemic chemotherapy, immunotherapy, or chemotherapy following radiation therapy.
* Patients are eligible for the study if their most recent standard-of-care MRI, used to assess disease location and extent, raises the question of tumor recurrence versus treatment-related changes. This concern can be noted by the radiologist or other members of the multidisciplinary care team, such as during a multidisciplinary conference. Additionally, if there are clinical concerns based on evolving exam findings or symptoms, and the treating physician suspects progression versus treatment-induced changes, the patient is also eligible for the study.
* Be able to lie still for 30-60 minutes during the imaging procedure
* Willing and able to undergo PET/MRI or PET/CT
* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:

  * The subject has their own prescription for the medication
  * The informed consent process is conducted prior to the self-administration of this medication
  * They come to the research visit with a driver

Exclusion Criteria:

* Subject unable or unwilling to provide informed consent
* Subject is pregnant
* Subject with contraindication(s) to or inability to undergo a PET/MR or PET/CT
* Known allergy to 18F-Fluciclovine or any of its excipients

Where it's running

• University of Wisconsin
  Madison, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Michael Veronesi, MD, PhD — University of Wisconsin, Madison
• Study coordinator: Radiology Studies
• Email: radstudy@uwhealth.org
• Phone: 608-282-8349

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer

  This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.

  Recruiting Instituto de Investigación Sanitaria Aragón · Zaragoza, Zaragoza · NCT07779109

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• What causes vulnerability in older adults with serious diseases and how it affects care decisions

  This study tests how often vulnerability factors appear in older adults with serious illnesses and how these factors influence treatment timing, survival, and quality of life.

  Recruiting Tampere University Hospital · Tampere · NCT07740239

• Seeing what cancer patients eat during radiation treatment using a mobile food diary

  This study tests whether patients undergoing radiation therapy can consistently use a mobile food diary app to log their daily meals.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07682714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.